Press Releases April 13, 2026 08:00 PM

Antalpha Platform Holding Company Announces Resignation of Chief Operating Officer and Chief Executive Officer, U.S. and EMEA

Antalpha announces the resignation of COO and CEO for U.S. and EMEA operations with transitional advisory role

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ANTA

Antalpha Platform Holding Company, a Nasdaq-listed fintech specializing in digital asset financing and risk management, announced the resignation of Mr. Derar Islim as Chief Operating Officer and Chief Executive Officer for its U.S. and EMEA operations effective April 30, 2026. Mr. Islim will continue as an advisor to facilitate a smooth transition. The company expressed gratitude for his leadership and anticipates continued growth.

Antalpha Platform Holding Company Announces Resignation of Chief Operating Officer and Chief Executive Officer, U.S. and EMEA
ANTA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Resignation of COO and CEO for U.S. and EMEA operations effective April 30, 2026.
  • Mr. Derar Islim to remain as an advisor to ensure orderly transition.
  • Antalpha focuses on financing, tech and risk management solutions in the digital asset industry, impacting fintech and digital asset sectors.

SINGAPORE, April 14, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (“Antalpha” or the “Company”) (Nasdaq: ANTA), a leading fintech company specializing in providing financing, technology, and risk management solutions to institutions in the digital asset industry, today announced that Mr. Derar Islim has resigned from his roles as the Company’s Chief Operating Officer and Chief Executive Officer for its U.S. and EMEA operations, effective April 30, 2026.

In connection with his resignation, Mr. Islim will continue to serve as an advisor to ensure a smooth and orderly transition.

“On behalf of the Company, I want to express our sincere gratitude to Derar for his leadership and contributions to Antalpha,” said Mr. Jin Xin, CEO of Antalpha. “Derar has played an important role in his tenure with us, and we wish him every success in his future endeavors.”

Mr. Islim commented, “I am grateful for the opportunity to work alongside the Antalpha team. I look forward to supporting the Company’s continued growth in my advisory capacity.”

About Antalpha

Antalpha is a leading fintech company specializing in providing financing, technology, and risk management solutions to institutions in the digital asset industry. Antalpha offers Bitcoin supply chain and margin loans through the Antalpha Prime technology platform, which allows customers to originate and manage their digital assets loans, as well as monitor collateral positions with near real-time data.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about Antalpha’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Antalpha’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Antalpha does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contacts
Investor Relations: [email protected]


Risks

  • Potential disruption in management during leadership transition affecting operational continuity.
  • Uncertainty about future leadership may impact investor confidence.
  • Risks associated with forward-looking statements and evolving regulatory landscape for digital assets.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026